Handelsavisen
prelaunch
Companies Healthcare AURX.PK
AU
AURX.PK OTC Pharmaceuticals & Medical Research

Aurx.Pk

$1,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-76,0 %
ROE
262,6 %
Net margin
-75,8 %
Debt / equity
-0,52
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

AURX.PK operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, primarily generating revenue through product sales and research activities.

Business. AURX.PK operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, primarily generating revenue through product sales and research activities.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target3,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
3,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
262,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning AURX.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to AURX.PK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    AURX.PK operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, primarily generating revenue through product sales and research activities.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    AURX.PK exhibits a negative equity position of -$956,560, indicating a significant financial challenge, and a debt-to-equity ratio of -0.52, which suggests the company is leveraging debt to fund operations. The liquidity position is moderate, with a current ratio of 1.06, implying the company has just enough current assets to cover its current liabilities. The operating cash flow is negative at -$864,970, and the free cash flow is -$2,701,520, indicating the company is not generating sufficient cash from operations to sustain or grow its business.

    Profitability metrics show a return on equity of 2.63, which is positive but modest, and a return on assets of -1.36, indicating that the company is not effectively utilizing its assets to generate profit. The gross profit of $2,217,960 is offset by a net loss of -$2,512,220, highlighting the company's struggle to convert gross profit into net income.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which increases its exposure to market-specific risks. The capital expenditure of -$274,760 suggests the company is not investing in long-term growth, which could limit its future capacity to expand or innovate.

    Looking ahead, the company is expected to maintain a negative operating income, with no significant improvement in the near term. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the company's negative net cash position after subtracting total debt is a key flag.

    Recent investor relations data show a mean price target of $3.00, with a median and high price target also at $3.00, and a mean recommendation of 2.00, indicating a cautious outlook from analysts. No strong buy recommendations were issued, with only one buy recommendation and no holds, suggesting limited confidence in the stock's near-term performance.

    Key takeaways
    • AURX.PK is operating with a negative equity position and a negative net cash position, indicating significant financial distress.
    • The company's liquidity is moderate, with a current ratio of 1.06, but its operating and free cash flows are negative, signaling poor cash generation.
    • The return on equity is positive but low, while the return on assets is negative, indicating inefficient asset utilization.
    • The company is not investing in capital expenditures, which could hinder future growth and innovation.
    • Analysts have a cautious outlook, with a mean price target of $3.00 and no strong buy recommendations.
    • The company's revenue is concentrated in a single segment, increasing its exposure to market-specific risks.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$956.6k
    Net cash
    -$500.0k
    Current ratio
    1.1
    Debt / equity
    -0.5
    ROA
    -1.4%
    ROE
    2.6%
    Cash conversion
    34.0%
    CapEx / revenue
    -8.3%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceuticals & Medical Research15,2B node revenueKLAR 23,0%BNTX 21,4%EXEL 15,2%MDGL 6,3%INSM 4,0%VCYT 3,4%MDXG 2,8%AVIR 2,3%Other 21,6%
    Source: company disclosures · own-taxonomy revenue-covered setAURX 0,0% · rank #63 of 109

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs AURX · multiples and returns
    KL
    KLAR
    KLAR.ST
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BN
    BNTX
    Biontech SE
    $92,25
    23,3B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    EX
    EXEL
    Exelixis Inc
    $55,06
    14,7B USD
    P/E
    19,5x
    vs self
    Div yield
    vs self
    ROE
    40,4 %
    vs self
    MD
    MDGL
    Madrigal Pharmaceuticals Inc
    $482,00
    11,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -47,8 %
    vs self
    IN
    INSM
    Insmed Inc
    $107,46
    23,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -160,2 %
    vs self
    VC
    VCYT
    Veracyte Inc
    $45,30
    3,6B USD
    P/E
    55,5x
    vs self
    Div yield
    vs self
    ROE
    5,1 %
    vs self
    MD
    MDXG
    Mimedx Group Inc
    $4,27
    636,0M USD
    P/E
    11,1x
    vs self
    Div yield
    vs self
    ROE
    18,9 %
    vs self
    AV
    AVIR
    Atea Pharmaceuticals Inc
    $4,61
    P/E
    vs self
    Div yield
    vs self
    ROE
    -57,5 %
    vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,03
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-10 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,03
    Revenueno estimateno estimate5,4M USD
    Operating incomeno estimateno estimateno estimate
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$3,00 · Median $3,00
    Low $3,00High $3,00
    EPS surprise
    −66,7 %
    reported vs consensus · miss
    Revenue surprise
    −38,1 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$3,00
    Mean$3,00
    Median$3,00
    High$3,00
    Spot$1,00
    +200.0 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-75,9 %Above median
    Net Margin-75,8 %Above median
    ROE262,6 %Best in class
    Capex / Rev-8,3 %Bottom quartile
    D/E-0,52Best in class
    Cash Conv0,34Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • AURX.PK Market data — financials · 2026-05-27
    • Nuo Therapeutics Inc Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    75shares short0.0% vs prior
    1days to cover
    482fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    AURX.PKCanonical
    OTC · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -8.1%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 261.8%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 55.2%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -286.2%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 61.2%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 93.5%Derived (calculated)
    • Return on assets (FY 2025-12-31): -136.1%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 77.3%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): -2.93xDerived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -2.4%Derived (calculated)
    • Return on equity (FY 2025-12-31): 262.6%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): 108.8%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 0.0%Derived (calculated)
    • Current ratio (FY 2025-12-31): 1.06xDerived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 314.7%Derived (calculated)
    • Cash & equivalents (annual): USD 548.95KSEC XBRL filing
    • Shareholders' equity (annual): USD -956.56KSEC XBRL filing
    • Operating income (annual): USD -2.52MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
    • Operating cash flow (annual): USD -864.97KSEC XBRL filing
    • Gross profit (annual): USD 2.22MSEC XBRL filing
    • Total assets (annual): USD 1.85MSEC XBRL filing
    • Cost of revenue (annual): USD 1.1MSEC XBRL filing
    • Net income (annual): USD -2.51MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage